Introduction
Methods
Protocol and registration
Literature search and selection
Data extraction
Quality appraisal
Data synthesis and statistical analysis
Result
Search results
Study characteristics and quality assessment
Study ID | First author | Year of publication | Study design | Sample size(n) | Follow-up period | Outcomes | |
---|---|---|---|---|---|---|---|
LD-IVIg | HD-IVIg | ||||||
1 | Bao H [26] | 2017 | RCT | 44 | 44 | 3 months | ER; DR; AR |
2 | He WD [27] | 2017 | RCT | 48 | 48 | 3 months | ER DR; AR Time of PC starting to rise; Time of PC rising to normal; Time of achieving hemostasis |
3 | Hou ZH [35] | 2021 | RCT | 58 | 58 | Not reported | ER |
4 | Ji LJ [29] | 2022 | RCT | 46 | 46 | Not reported | ER; AR Time of PC rising to normal Time of achieving hemostasis |
5 | Luo F [42] | 2017 | RCT | 45 | 45 | Not reported | ER Time of PC starting to rise; Time of achieving hemostasis |
6 | Su BX [44] | 2016 | RCT | 38 | 40 | 3 months | ER; DR; AR Time of PC starting to rise; Time of PC rising to normal; Time of achieving hemostasis |
7 | Qin HZ [38] | 2015 | RCT | 40 | 40 | 3 months | ER; DR; AR Time of PC starting to rise; Time of PC rising to normal; Time of achieving hemostasis |
8 | Yang YX [47] | 2019 | RCT | 34 | 33 | 3 months | ER; DR; AR Time of achieving hemostasis |
9 | Yu ZJ [48] | 2018 | RCT | 60 | 60 | 3 months | ER; DR Time of PC starting to rise; Time of PC rising to normal; Time of achieving hemostasis |
10 | Zhu W [50] | 2014 | RCT | 65 | 65 | Not reported | ER; AR |
11 | Zhao SL [49] | 2018 | RCT | 17 | 17 | 6 months | ER; DR; AR Time of PC starting to rise; Time of PC rising to normal Time of achieving hemostasis |
12 | Feng L [30] | 2019 | RCT | 34 | 34 | 3 months | ER; DR; AR Time of PC starting to rise; Time of PC rising to normal |
13 | He WH [34] | 2019 | RCT | 31 | 31 | 3 months | ER; DR Time of PC starting to rise; Time of PC rising to normal |
14 | Shi L [43] | 2019 | RCT | 32 | 32 | Not reported | ER; AR Time of PC rising to normal; Time of achieving hemostasis |
15 | Liang CJ [37] | 2017 | RCT | 28 | 26 | Not reported | ER; AR Time of PC rising to normal; Time of achieving hemostasis |
16 | Tan YF [39] | 2016 | RCT | 28 | 28 | 3 months | ER; DR Time of PC starting to rise; Time of PC rising to normal |
17 | Liu LK [40] | 2003 | RCT | 45 | 45 | Not reported | ER |
18 | Yang B [46] | 2013 | RCT | 55 | 55 | Not reported | ER; AR Time of PC rising to normal; Time of achieving hemostasis |
19 | Wang Y [45] | 2022 | RCT | 19 | 19 | Not reported | ER |
20 | Jin Y [36] | 2020 | RCT | 25 | 25 | Not reported | ER |
21 | Yang Y [32] | 2022 | RCT | 51 | 51 | Not reported | ER Time of PC starting to rise; Time of PC rising to normal; Time of achieving hemostasis |
22 | Hu XL [33] | 2018 | RCT | 50 | 50 | 3 months | ER; DR |
23 | Gong CX [31] | 2016 | Cohort study | 30 | 33 | 18 months | ER; DR |
24 | Liu YY [41] | 2008 | Cohort study | 27 | 32 | Not reported | ER |
25 | Huang HY [28] | 2022 | Cohort study | 41 | 41 | Not reported | ER; AR |
Study | Gender F/M | Age (years) | PC before treatment (×109) | Dose of IVIg (g/kg per day×days) | Type and dose of intravenous glucocorticoid (mg/kg per day×days) | ||||
---|---|---|---|---|---|---|---|---|---|
LD-IVIg | HD-IVIg | LD-IVIg | HD-IVIg | LD-IVIg | HD-IVIg | LD-IVIg | HD-IVIg | ||
Bao H [26] | 21/23 | 19/25 | 5.94 ± 1.26 | 6.04 ± 1.31 | 13.64 ± 5.26 | 14.15 ± 5.19 | 0.2 × 5 | 0.4 × 5 | DXMS (1.0 × 5) |
He WD [27] | 25/23 | 22/26 | 5.22 ± 1.13 | 5.51 ± 1.02 | < 20 (17 patients) ≥ 20 (31 patients) | < 20 (14 patients) ≥ 20 (34 patients) | 0.2 × 5 | 0.4 × 5 | DXMS (1.5 × 5) |
Hou ZH [35] | 25/33 | 27/31 | 5.3 ± 1.5 | 5.1 ± 1.3 | 19.97 ± 5.11 | 20.15 ± 5.16 | 0.2 × 5 | 0.4 × 5 | DXMS (0.5 × 5) |
Ji LJ [29] | 22/24 | 23/23 | 3.80 ± 1.25 | 3.85 ± 1.20 | 20.10 ± 5.03 | 20.12 ± 4.88 | 0.2 × 5 | 0.4 × 5 | DXMS (1.5 × 5) |
Luo F [42] | 44/46 | 10.23 ± 3.13 | < 20 | 0.2 × 5 | 0.4 × 5 | DXMS (1.0 × 5) | |||
Su BX [44] | 20/18 | 20/20 | 6.2 ± 1.1 | 5.8 ± 1.2 | 17.2 ± 6.1 | 16.4 ± 5.9 | 0.2 × 5 | 0.4 × 5 | DXMS (1.0 × 5) |
Qin HZ [38] | Not reported | 5.6 ± 1.7 | < 25 | 0.2 × 5 | 0.4 × 5 | DXMS (1.5 × 5) | |||
Yang YX [47] | 15/19 | 16/17 | 5.96 ± 1.08 | 5.90 ± 1.01 | 13.90 ± 5.23 | 13.78 ± 5.18 | 0.2 × 5 | 0.4 × 5 | DXMS (1.0 × 5) |
Yu ZJ [48] | 27/33 | 26/34 | 5.4 ± 1.6 | 5.6 ± 1.2 | < 10 (52 patients) 10–25 (68 patients) | 0.2 × 5 | 0.4 × 5 | DXMS (0.5 × 5) | |
Zhu W [50] | 31/34 | 29/36 | 6.14 ± 2.47 | 6.21 ± 2.83 | < 10 (27 patients) 10–25 (38 patients) | < 10 (30 patients) 10–25 (35 patients) | 0.2 × 5 | 0.4 × 5 | DXMS (0.5 × 5) |
Zhao SL [49] | 6/11 | 9/8 | 8.1 ± 2.1 | 7.7 ± 1.9 | 14.9 ± 4.5 | 14.6 ± 4.9 | 0.2 × 5 | 0.4 × 5 | DXMS (0.5 × 5) |
Feng L [30] | 38/30 | 2–15 | 3–77 | 0.2 × 5 | 0.4 × 5 | MP (20 × 3) | |||
He WH [34] | 10/21 | 11/20 | 9 months- 9 years | 9 months- 10 years | Not reported | 0.2 × 5 | 0.4 × 5 | DXMS (0.5 × 5) | |
Shi L [43] | 15/17 | 16/16 | 6.41 ± 1.26 | 6.65 ± 1.33 | 20.02 ± 5.13 | 19.95 ± 4.98 | 0.2 × 5 | 0.4 × 5 | DXMS (0.5 × 7) |
Liang CJ [37] | Not reported | 3 months-14 years | 22.65 ± 15.7 | 28.21 ± 18.82 | 0.2 × 5 | 0.4 × 5 | DXMS (0.5 × 5) | ||
Tan YF [39] | Not reported | 5.6 ± 1.8 | 14–57 | 0.2 × 5 | 0.4 × 5 | DXMS (1.0 × 5) | |||
Liu LK [40] | 44/46 | 7.35 ± 1.21 | Not reported | 0.2 × 5 | 0.4 × 5 | MP (20 × 4) | |||
Yang B [46] | 26/29 | 28/27 | 6.80 ± 1.28 | 6.23 ± 1.22 | 19.98 ± 5.06 | 20.15 ± 5.08 | 0.4 × 2 | 1.0 × 2 | No |
Wang Y [45] | 9/10 | 8/11 | 6.66 ± 1.28 | 6.78 ± 1.12 | 18.12 ± 2.44 | 18.08 ± 2.65 | 0.3 × 2 | 0.4 × 5 | DXMS (0.5 × 7) |
Jin Y [36] | 8/17 | 9/16 | 2.82 ± 2.17 | 2.46 ± 1.86 | < 20 × 109/L | 0.4 × 2 | 1.0 × 2 | No | |
Yang Y [32] | 30/21 | 22/29 | 3.9 ± 1.5 | 3.8 ± 1.3 | Not reported | 0.2 × 3 | 0.4 × 3 | MP (20 × 4) | |
Hu XL [33] | 12/38 | 11/39 | 4.21 ± 0.26 | 4.05 ± 0.12 | Not reported | 0.2 × 5 | 0.4 × 5 | DXMS (1.0 × 5) | |
Gong CX [31] | 18/12 | 18/15 | 2–16 | 3–16 | 1–19 | 0.2 × 5 | 0.4 × 5 | No | |
Liu YY [41] | 28/31 | 4.6(0.8-8.0) | 6–21 | 1.0 × 1 | 0.4 × 5 | DXMS (0.4 × 3) | |||
Huang HY [28] | 22/19 | 21/20 | 6.20 ± 2.46 | 6.24 ± 2.50 | 20.23 ± 5.26 | 20.14 ± 5.69 | 0.2 × 5 | 0.4 × 5 | DXMS (1.0 × 5) |